IPO registrations (S-1, F-1) · Registrants
Korro Bio, Inc.
- SEC CIK
- 1703647 · filings on EDGAR ↗
- Former names
- Frequency Therapeutics, Inc. (2017–2023)
- Registration
- Form S-1, first filed 2019-09-06, last 2024-05-14; 3 initial registrations, 3 amendments
- Outcome
- Final prospectus filed 2019-10-04; declared effective 2019-10-02
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 60 FIRST STREET, 2ND FLOOR, SUITE 250, Cambridge, MA 02141
- EIN
- 47-2324450
- Ticker
- KRRO (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Korro Bio, Inc. on the corporate pages
Offering terms
- Proposed price range
- $14.00–$16.00 per share (S-1/A filed 2019-09-23)
- Final price
- $14.00 per share, within the range (424B4 filed 2019-10-04, an initial public offering)
- Shares sold
- 6,000,000
- Gross proceeds
- $84,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol FREQ
- Lead underwriters
- J.P. Morgan
- Syndicate
- Goldman Sachs; Cowen
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form 5500 plan sponsor: FREQUENCY THERAPEUTICS, INC. EXACT (EIN (EXACT))
- Form D issuer: Frequency Therapeutics, Inc. EXACT (CIK (EXACT))
- SEC filer: Frequency Therapeutics, Inc. EXACT (CIK (EXACT))
- Person page: David L Lucchino Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
- Person page: James E Flynn Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwnerOther))
Filings 18
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2019-09-06 | S-1 | S-1 (registration) | Frequency Therapeutics, Inc. | 0001193125-19-239976 ↗ |
| 2019-09-23 | S-1/A | S-1/A (amendment) | Frequency Therapeutics, Inc. | 0001193125-19-251257 ↗ |
| 2019-10-02 | EFFECT | EFFECT (declared effective) | Frequency Therapeutics, Inc. | 9999999995-19-002226 ↗ |
| 2019-10-04 | 424B4 | 424B4 (final prospectus) | Frequency Therapeutics, Inc. | 0001193125-19-262758 ↗ |
| 2020-08-28 | S-1 | S-1 (registration) | Frequency Therapeutics, Inc. | 0001193125-20-234689 ↗ |
| 2020-09-03 | EFFECT | EFFECT (declared effective) | Frequency Therapeutics, Inc. | 9999999995-20-002362 ↗ |
| 2020-11-24 | EFFECT | EFFECT (declared effective) | Frequency Therapeutics, Inc. | 9999999995-20-003307 ↗ |
| 2023-09-29 | EFFECT | EFFECT (declared effective) | Frequency Therapeutics, Inc. | 9999999995-23-002873 ↗ |
| 2023-12-01 | S-1/A | S-1/A (amendment) | Korro Bio, Inc. | 0001193125-23-287451 ↗ |
| 2023-12-20 | S-1/A | S-1/A (amendment) | Korro Bio, Inc. | 0001193125-23-299978 ↗ |
| 2023-12-22 | EFFECT | EFFECT (declared effective) | Korro Bio, Inc. | 9999999995-23-003727 ↗ |
| 2024-03-27 | EFFECT | EFFECT (declared effective) | Korro Bio, Inc. | 9999999995-24-000737 ↗ |
| 2024-05-14 | S-1 | S-1 (registration) | Korro Bio, Inc. | 0001193125-24-138296 ↗ |
| 2024-05-22 | EFFECT | EFFECT (declared effective) | Korro Bio, Inc. | 9999999995-24-001627 ↗ |
| 2024-12-06 | EFFECT | EFFECT (declared effective) | Korro Bio, Inc. | 9999999995-24-003700 ↗ |
| 2024-12-09 | EFFECT | EFFECT (declared effective) | Korro Bio, Inc. | 9999999995-24-003704 ↗ |
| 2024-12-09 | EFFECT | EFFECT (declared effective) | Korro Bio, Inc. | 9999999995-24-003707 ↗ |
| 2026-03-20 | EFFECT | EFFECT (declared effective) | Korro Bio, Inc. | 9999999995-26-000894 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2019-09-23 | S-1/A | registration statement | $14.00–$16.00 | 6,700,000 | - | Nasdaq FREQ | 3 | primary document; range, shares headline, cover names 3 | document ↗ | |
| 2019-10-04 | 424B4 | final prospectus | $14.00 | 6,000,000 | $84,000,000 | Nasdaq FREQ | 3 | primary document; price sentence, shares headline, proceeds table, cover names 3 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Alexandria Venture Investments, LLC | TenPercentOwner | 2 | 2019 | ||
| BARBERICH TIMOTHY J | Director | 7 | 2019–2022 | ||
| COHEN MARC A | Director | 7 | 2019–2022 | ||
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | TenPercentOwnerOther | 2 | 2019 | ||
| Deerfield Mgmt IV, L.P. | TenPercentOwnerOther | 2 | 2019 | ||
| Deerfield Mgmt L.P. | TenPercentOwnerOther | 2 | 2019 | ||
| Deerfield Private Design Fund IV, L.P. | TenPercentOwnerOther | 2 | 2019 | ||
| Deerfield Special Situations Fund, L.P. | TenPercentOwnerOther | 2 | 2019 | ||
| Flynn James E | TenPercentOwnerOther | 2 | 2019 | person page Fuzzy | |
| Hilt Dana Charles | Officer | Chief Medical Officer | 4 | 2019–2021 | |
| Huang Michael | Director | 5 | 2019–2022 | ||
| Karp Jeffrey M. | TenPercentOwner | 1 | 2019 | ||
| LANGER ROBERT | Director | 6 | 2019–2022 | ||
| LeBel Carl | Officer | Chief Development Officer | 12 | 2019–2023 | |
| Loose Christopher R. | Officer | Chief Scientific Officer | 45 | 2019–2023 | |
| Lucchino David L. | Director; Director,Officer | President and CEO | 67 | 2019–2024 | person page Fuzzy |
| MARCUS JOEL S | Director; Director,TenPercentOwner | 12 | 2019–2022 | ||
| McLean William J. | TenPercentOwner | 2 | 2019 | ||
| Mitrano Richard J. | Officer | VP, Finance; VP Finance & Operations | 28 | 2019–2023 | |
| DEERFIELD PARTNERS, L.P. | TenPercentOwnerOther | 1 | 2019 | ||
| Arnold Wendy S | Officer | Chief People Officer | 10 | 2020–2023 | |
| FELDMANN CYNTHIA L | Director | 5 | 2020–2022 | ||
| PFREUNDSCHUH PETER P. | Officer | Chief Financial Officer | 7 | 2020–2022 | |
| Bookman Michael | Officer | General Counsel and Secretary | 2 | 2021 | |
| McCubbin Quentin | Officer | Chief Manufacturing Officer | 10 | 2021–2023 | |
| Agarwal Vineet | Officer | Chief Financial Officer | 5 | 2023–2025 | |
| Aiyar Ram | Director,Officer | President and CEO | 7 | 2023–2026 | |
| Atlas Venture Associates Opportunity II, LLC | TenPercentOwner | 2 | 2023–2024 | ||
| Atlas Venture Associates Opportunity II, LP | TenPercentOwner | 2 | 2023–2024 | ||
| Atlas Venture Associates XI, LLC | TenPercentOwner | 1 | 2023 | ||
| Atlas Venture Associates XI, L.P. | TenPercentOwner | 1 | 2023 | ||
| Atlas Venture Fund XI, L.P. | TenPercentOwner | 1 | 2023 | ||
| Atlas Venture Opportunity Fund II, L.P. | TenPercentOwner | 2 | 2023–2024 | ||
| BASKETT FOREST | TenPercentOwner | 3 | 2023–2026 | ||
| Behbahani Ali | Director; Director,TenPercentOwner | 7 | 2023–2026 | ||
| Bermingham Nessan | Director | 5 | 2023–2026 | ||
| Chang Carmen | TenPercentOwner | 3 | 2023–2026 | ||
| Chappell Todd | Officer | Chief Operating Officer | 7 | 2023–2026 | |
| Colletti Steve | Officer | Chief Scientific Officer | 2 | 2023 | |
| Florence Anthony A. Jr. | TenPercentOwner | 3 | 2023–2026 | ||
| FORMELA JEAN FRANCOIS | Director | 13 | 2023–2026 | ||
| Makhzoumi Mohamad | TenPercentOwner | 3 | 2023–2026 | ||
| Mathers Edward T | TenPercentOwner | 3 | 2023–2026 | ||
| NEA 17 GP, LLC | TenPercentOwner | 3 | 2023–2026 | ||
| NEA Partners 17, L.P. | TenPercentOwner | 3 | 2023–2026 | ||
| New Enterprise Associates 17, L.P. | TenPercentOwner | 3 | 2023–2026 | ||
| PEARSON TIMOTHY R | Director | 5 | 2023–2026 | ||
| SANDELL SCOTT D | TenPercentOwner | 3 | 2023–2026 | ||
| Walker Paul Edward | TenPercentOwner | 3 | 2023–2026 | ||
| Walker Shelby J. | Officer | See Remarks | 2 | 2023 | |
| Yang Rick | TenPercentOwner | 3 | 2023–2026 | ||
| Meyers Rachel | Director | 5 | 2023–2026 | ||
| Olugemo Olukemi | Officer | Chief Medical Officer | 3 | 2024–2025 | |
| Knobil Katharine | Director | 4 | 2024–2026 | ||
| Cerio Jeffrey | Officer | General Counsel | 7 | 2024–2026 | |
| Dolan Oliver | Officer | Senior Vice President, Finance | 8 | 2025–2026 | |
| Vincent Loic A | Officer | Chief Scientific Officer | 6 | 2025–2026 | |
| Lynx1 Capital Management LP | TenPercentOwner | 3 | 2026 | ||
| Nichols Weston | TenPercentOwner | 3 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2020-07-27 | Frequency Therapeutics, Inc. | Biotechnology | $42,301,944 | $42,301,944 | 18 | 1 |
| 2019-07-23 | Frequency Therapeutics, Inc. | Biotechnology | $61,999,366 | $61,999,366 | 80 | 1 |
| 2017-04-14 | Frequency Therapeutics, Inc. | Biotechnology | $32,000,000 | $32,000,000 | 90 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Plan sponsor | FREQUENCY THERAPEUTICS, INC. | MA | Form 5500 (employee benefit plans) | EIN (EXACT) |
| Plan sponsor | KORRO BIO, INC | MA | Form 5500 (employee benefit plans) | name and state |
| Form D issuer | Frequency Therapeutics, Inc. | MA | Form D private offerings | CIK (EXACT) |
| Form D issuer | KORRO BIO, INC. | MA | Form D private offerings | name and state |
| Patent assignee | KORRO BIO, INC. | MA | Patents (USPTO) | name and state |
| SEC filer | Korro Bio, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Korro Bio, Inc. | MA | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | FREQUENCY THERAPEUTICS, INC. | EIN (EXACT) | ||
| Person page | David L Lucchino | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) | |
| Person page | James E Flynn | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwnerOther) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, MA first:
- ERGO SCIENCE CORP MA
- MILLENNIUM PHARMACEUTICALS INC MA
- ESSENTIAL THERAPEUTICS INC MA
- ARQULE INC MA
- ASCENT PEDIATRICS INC MA
- EPIX Pharmaceuticals, Inc. MA
- PRAECIS PHARMACEUTICALS INC MA
- PARATEK PHARMACEUTICALS INC MA
- PREDIX PHARMACEUTICALS HOLDINGS INC MA
- CervoMed Inc. MA
In other datasets, the same topic (Health) in MA:
- Nonprofit: ABBIE M GRIFFIN HOSPITAL FUND (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health